CCL2 and atherosclerosis: Animal studies have shown that administration of sRAGE remarkably stabilizes atherosclerotic plaque, and inhibits inflammatory factors such as cyclooxygenase-2 (COX-2), VCAM-1, and monocyte chemoattractant protein-1 (MCP-1), thereby attenuating atherosclerosis progression [36–38].